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Abstract: 
 
This study aims to prepare topical salicylic acid and lactic acid 
microemulsion with a different formulations applied using the minimum 
amount of Tweens. The sugar surfactant used in this study is sorbitan 
monooleate (Tween 80). Short chain alcohol used as a co-surfactant which is 
propylene glycol. The oil phase used is castor oil. The aqueous phase is 
purified water. Also this study aims to prepare a co-crystal paradigm between 
salicylic acid and lactic acid as the active pharmaceutical ingredients, in 
presence of using different co-solvents. 
 
In this research, we studied the effect of different percentage of surfactants on 
the phase behavior of the systems suggested at different temperatures 25, 37 
and 45°C. We also explored the effect of adding co-surfactant (propylene 
glycol) on the phase behavior. The addition of propylene glycol as a co-
surfactant contributes clearly in forming much smallest and stable micro 
emulsion droplet size besides giving pliability to the infected skin. Lastly the 
phase behavior of sorbitan monooleate studied as a function of temperature 
and surfactant concentration; that is presented in the form of the well known 
phase diagram that shows an isotropy microemulsion solution (using visual 
inspection, cross polarizer and dynamic light scattering) as low as 4% water 
addition at all temperatures (25˚C, 37˚C& 45˚C).  
 
Also in this research, we studied the ability of different co-solvents used in 
the formation of co-crystal paradigms, such as ethanol (96%), methanol 
(99%), diethyl ether and acetonitrile either in reflux or grinding techniques. 
The co-crystal paradigm was obtained in all reflux techniques applied 
successfully; more than 80% from the grinding technique of the samples 
obtained creates a merged compound   successfully. All paradigms are tested 
using Fourier Transform Infra Red spectroscopy (FTIR) and the melting 
point range is tested for part of them. The co-crystals obtained were tested for 
solubility modifications and the results show a clear change in their solubility 
to be sparingly soluble to soluble in water. Also the co-crystal solids were 
tested for their melting point and the variation change observed is dependent 
on the target active pharmaceutical concentration and depending on the molar 
ratio for each co-crystal tested. But even so the melting point was changed to 
be lower than pure salicylic acid melting point and higher than lactic acid.
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1.  Introduction: 
 
To make a review about topical microemulsion therapeutic meaning let us consider  
these two therapeutic words individually, what do we mean by topical?, And what 
is microemulsion?, What are the main microemulsion component? 
 
1.1 Surfactants: 
 
Surfactants (or „surface active agents‟) are organic compounds with at least one 
lyophilic („solvent-loving‟) group and one lyophobic („grease-loving‟) group in the 
molecule. If the solvent in which the surfactant is to be used is water or an aqueous 
solution, then the respective terms „hydrophilic, water loving,‟ and „hydrophobic, 
grease loving,‟ are used. In the simplest terms, a surfactant contains at least one 
non-polar group and one polar (or ionic) group and is represented in a somewhat 
stylized form shown in Figure 1. Adsorption of a surfactant at the water/oil 
interface produces a surface with a significant very low interfacial energies, the 
formation of this type of low interfacial energy surface is the basis of the stability 
of most oil and water emulsions and all microemulsions as shown in Figure 2 [1]. 
 
 
Figure 1 Schematic illustration of surfactant molecule .[1] 
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Figure 2 Illustration of the effect of an adsorbed surfactant  
layer on the interfacial energy between oil and water .[1] 
 
 
The most useful chemical classification of surfactant is based on the nature of the 
hydrophilic part (head), with subgroups based on the nature of the hydrophobic part 
(tail). The four basic classes of surfactants are [2]:Anionic in which the hydrophilic 
part is a negatively charged group, cationic in which the hydrophilic part is a 
positive charge, nonionic the hydrophilic has no charge, but derives its water 
solubility from highly polar groups such as sugars and amphoteric groups 
(zwitterionic). It is not surprising that the selection of a suitable surfactant for a 
given application can become a significant problem. Thus an empirical numbering 
system has been developed to enable the correct type of surfactant to be chosen. 
The system is called the „hydrophile–lipophile balance‟ (HLB). Therefore 
polysorbate 80 (Tween 80) is selected in this project preparation to achieve the 
drug product microemulsion formation since it had an HLB=15.0 
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Self-Assembled Surfactant Structures: 
 
In aqueous solution dilute concentrations of surfactant act much as normal 
electrolytes, but at higher concentrations very different behavior results will be 
obtained. This behavior is explained in terms of the formation of organized 
aggregates of large numbers of surfactant molecules called micelles as shown in 
Fig. 3. In which the lipophilic parts of the surfactants will be associated in the 
interior of the aggregate leaving hydrophilic parts to face the aqueous medium. 
Meanwhile, that happens at a specific, higher, surfactant concentration, known as 
the critical micelle concentration (CMC). Besides, the physico-chemical properties 
of surfactants vary markedly above and below the CMC value [2,3]. 
 
 
 
Figure 3 Schematic diagram of a surfactant micelle [3]. 
 
 
In addition, acting surfactants at oil/water interface formed a large number of self-
assembled structures depending on the type of surfactants [4]. Spherical normal 
micelles (L1) are formed at high water content (oil/water), while reversed micelle 
(L2) are formed at low water content (water/oil), between these two extremes 
different isotropic and anisotropic liquid crystalline phases with decreased water 
content or increased temperature or electrolyte concentration may be formed. The 
following sequence of anisotropic liquid crystalline phase may take place for the 
surfactant systems as shown in Fig.4: 
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The variation and complexity of these structures has led to much research on 
potential industrial applications. However, microemulsion is the most important 
structures in which single low viscous isotropic phase formed in L1and L2 regions 
of the phase diagram. 
 
 
 
Figure 4 The fontell scheme, showing the idealized sequence 
 of association structures of surfactants [4]. 
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1.1.2 Sugar-Based Surfactants: 
 
Sugar-based surfactants are characterized by having the hydrophilic sugar head 
group and the hydrophobic alkyl chain. This structural feature provides unique 
physicochemical properties to these surfactants. Among the characteristic 
properties of Sugar-based surfactants, a frequently remarked fact is that they can be 
produced from renewable resources and exhibit excellent environmental behavior. 
Certainly, there is currently a clear tendency to replace conventional surfactants 
with more environmentally good naturally compounds. Although interest in Sugar-
based surfactant was traditionally, they have recently become the object of 
increasing attention for many researchers. The behavior of Sugar-based surfactants 
is also critically influenced by the nature of the substituent groups that are bounded 
to the individual monosaccharides. This substituent‟s can be of natural origin or 
semi natural quality. Whether they are natural or semi natural, the classification of 
Sugar-based surfactants falls into one of five categories, based primarily on the 
polysaccharide charge. These include: anionic, cationic, nonionic, amphoteric, and 
hydrophobically modified Sugar based surfactants [4]. It is clear from an industrial 
perspective that only a few carbohydrates fulfill the criteria of price, quality, and 
availability. Today, one of the most important sugar-based surfactants is sorbitan 
esters, which is used in pharmaceutical drugs such as polysorbate 80 (Tween 80), 
see figure 5. 
 
 
Figure 5 Polyoxyethylene (20) sorbitan monooleate (Tween 80), [4] 
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1.2 Alcohol Conventional Effects: 
 
Three effects of an alcohol additive in the formulation of microemulsion  have been 
mentioned so far [5]. First, it contributes to the general formulation as a co-
surfactant, slightly hydrophilic contribution for methanol and ethanol; lipophilic 
contribution for n-butanol and longer linear alcohols, Secondly, as a co-solvent. 
The alcohol will be adsorbed with the surfactant at the interface and changes the 
overall interaction of the amphiphilic film with the adjacent solvents. The longer 
alcohol chain will give a lower tendency to act as co-surfactant, because it is partly 
soluble in the oil phase. Consequently, the co-surfactant effect may be said to fade 
away. As the alcohol mostly partitions into the water or oil phase it behaves either 
as a co-solvent. When such alcohol co-solvents are present in small proportion, 
they might not mix uniformly in the bulk of the oil or water phase and they could 
exhibit a thirdly effect called lipophilic linker Fig. 6. 
 
 
 
 
Figure 6 Solubilisation improvement of a conventional  
          surfactant (a) by alipophilic linker (b) [5]. 
 
The high surfactant concentration required to formulate a microemulsion, usually 
remains a major concern for the user. In addition, much of the work on 
microemulsions has employed alcohols as co-surfactants and as co-solvent in order 
to decrease surfactant film rigidity, thus promoting microemulsion formation and 
delay the occurrence of liquid crystalline phases. Alcohol can also reduce the time 
needed for equilibration to be reached in multi phase systems [6]. 
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1.3 Microemulsion: 
 
Microemulsions are clear, thermodynamically stable, optically isotropic systems of 
at least a hydrophilic, a hydrophobic and an amphiphilic component 
(surfactants/co-surfactants). It is composed of submicron sized droplets that plays 
an important role to distinguish and characterize them from ordinary emulsions 
which are thermodynamically unstable
 
[7]. Also microemulsion  can be considered 
as small scale versions of emulsions with droplet dispersions either of oil-in-water 
(o/w) or of water-in-oil (w/o), with a size range in the order of 5−50 nm in drop 
radius. Microemulsions advantages include improvement in poorly drug solubility, 
enhancement of bioavailability, protection of the unstable drugs against 
environmental conditions and a long shelf life [8]. 
 
It is known that oil and water are not miscible at ambient temperature; a small 
amount of surfactant is able to co-solubilize them. Generally non-ionic surfactants 
are chosen because of their good coetaneous tolerance, lower irritation potential 
and toxicity, such as polysorbate 80 (Tween 80).  The co-surfactants even though 
being indispensable in the formulation of microemulsions, have exhibited toxicity 
such as ethanol
 
[9].  Microemulsion formulation has to be controlled accurately, 
which is very critical because of the high number of degrees of freedom in any 
practical case. This is why formulation is sometimes considered as earnestly magic 
formulation. Investigations the phase behavior of salicylic acid and lactic acid with 
a specified Castor oil using surfactants/co-surfactant introduced to use these two 
drugs in different formulations, for other routs of drug administration [10]. 
 
Microemulsion stabilized by sugar surfactants usually contains a co-surfactant/ co-
solvent. Since without a co-surfactant/ co-solvent only o/w microemulsions are 
formed, which is mainly due to the fact that the high hydrophilicity of sugar 
surfactants cannot be changed significantly by temperature variation [11]. The 
proposed co-surfactant  in this project is propylene glycol. 
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Microemulsion applications: 
 
Microemulsions had been used in a variety of chemical and industrial processes, 
such as in enhanced oil recovery, fuel, coatings and textile finishing, lubricants, 
cutting tots oils and corrosion inhibitors, detergency, cosmetics, agrochemicals, 
food , biotechnology, environmental remediation and detoxification, analytical 
applications , microemulsion  gel technique, liquid membranes and in 
pharmaceuticals  [12].  Microemulsion  applications as drug delivery would be in 
different routes of administrations, such as in Oral, Ophthalmic, Parenteral, Nasal, 
Periodontal, Drug Targeting, Antiacne, Antioxidants (in dermatological and 
cosmetic products), Antifungal, Antiviral, Ocular, Spermicidal, oral, mucosal, 
transdermal and dermal drug delivery.  
 
Drug delivery to or through the skin offers various advantages over oral and 
parenteral routes of drugs for local and systemic effects. However, the natural 
protective barrier nature of the skin poses a challenge to deliver drugs in 
therapeutic topical quantities [7]. Topical preparations mean in pharmacists that it 
will pertain to increase the absorption of the medicament (active drug agents) 
applied to a specific area of the body. So, topical microemulsion  is applied directly 
to or through the skin [13].   
 
The skin is the largest human organ of the integumentary system and also an 
excellent biological barrier against chemical and biological insult. It is about 2 mm 
in thickness and accounts for nearly 4% of the total body weight. It is composed of 
three major components: the epidermis, dermis, and subcutaneous fat layer 
(hypodermis). The epidermis layer, which is the outermost skin layer, it is typically 
50-150 μm in thickness and it contains the stratum corneum in the outer layer, 
which is the main barrier for the permeation of drugs across the skin). Stratum 
corneum is 10-20μm thick and made up of dead keratinized cells called 
corneocytes, which are embedded in a lipid matrix that renders the membrane 
practically impermeable to large and hydrophilic molecules [14, 15,16]. The goal in 
topical microemulsion is to maximize drug absorption in the systemic circulation. 
The rate and extent of drug penetration into different layers of skin and into 
systemic circulation are governed by the drug properties and formulation 
characteristics. 
 
One of the advantages of microemulsions lies in the „phase inversion‟ that takes 
place at a given water to oil concentration ratio. This means, at lower water content 
the microemulsion consists of very small water droplets dispersed in oil (W/O), 
while at higher water content the situation is reversed and the system consists of oil 
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droplets dispersed in water (O/W). Between these two phases exists an intermediate 
situation in which the system consists of layers of surfactant separating alternate 
layers of water and oil? By increasing the water content the droplets of water 
initially increase their radius slightly, and then the system passes directly to the o/w 
droplets situation. The existence of this kind of structural change has been 
predicted on the basis of many different measurements, such as x-ray, optical 
properties, dielectric properties, viscosity and NMR. From the thermodynamic 
point of view, microemulsions are rather complicated systems, mainly because of 
the existence of at least four components, and because of the electric double layer 
surrounding the droplets, or the rods, or the layers that contribute clearly to the free 
energy of the system. 
 
The microemulsion region is usually characterized by constructing ternary phase 
diagrams. The basic three components required to form a microemulsion are: an oil 
phase, an aqueous phase and a surfactant. If a co-surfactant is used, it may 
sometimes be represented at a fixed ratio to surfactant or to any component of the 
phase diagram as a single component, and treated as a single “pseudo-
component”. The relative amounts of these three components can be represented in 
a ternary phase diagram. The three components composing the system are each 
found at the head of the triangle, where their corresponding volume fraction is 
100%. The relative amounts of A, B and C are expressed in percentage of the 
selected parameter, such as: A%+B%+C%=100% [17]. 
 
 
Figure 7 Hypothetical phase regions of microemulsion systems [17] 
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1.4 Factors affecting drug release: 
  
 Amount of drug  
 
The large amount of drug incorporated in the internal phase leads to development 
of a concentration gradient between the internal and external phase, increasing the 
thermodynamics of the drug and providing for the diffusion of drug from the 
internal phase into the skin layers [16]. 
 
 Type and amount of surfactant 
 
Various types of surfactants have been reported in the use of topical 
microemulsions, such as oil in water or water in oil. The non-ionic surfactants are 
preferred over the anionic or cationic surfactants, since the latter are reported to be 
harsh on the skin. An inverse relationship exists between the amount of surfactant 
and drug permeation since a large amount of surfactant reduces the thermodynamic 
activity of the system hampering drug diffusion [18, 19]. 
 
  Amount of  alcohols 
 
Alcohols are used as skin penetration enhancers, and they are able to lower the 
microemulsion melting point and have been known to disorganize the stratum 
corneum lipid structure, enhancing the partitioning and permeation of drugs 
[20,21]. 
 
 Amount of water 
 
At low water concentrations, all water molecules are used in hydrating the polar 
heads of the surfactant molecule leaving no free water available for hydrating the 
stratum corneum, thus affecting the permeation of both lipophilic as well as 
hydrophilic drug that provides a strong force to push the drug molecules across skin 
layers [22, 23]. 
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1.5 Co-crystallization: 
 
Poorly water soluble drugs pose significant hurdles for drug bioavailability that in 
turn affect in vivo efficacy and safety in all stages of formulation. Among the 
biopharmaceutical properties, solubility remains a key issue with drugs often 
discarded during commercial production due to their low solubility. Improving the 
solubility of drugs is currently one of the main challenges for the pharmaceutical 
industry. Many approaches have been adopted for improving the aqueous solubility 
of drugs including micronisation, salt formation, emulsification, solubilisations 
using co-solvents. Over the last decade, there has been growing interests in the 
design of pharmaceutical co-crystals, which emerges as a potential method for 
enhancing the bioavailability of drugs with low aqueous solubility [24]. The ability 
to deliver the drug to the patient in a safe, efficient and cost effective manner 
depends largely on the physicochemical properties of the active pharmaceutical 
ingredient (API) in the solid state being studied.  
 
Co-crystals can be defined as crystalline complexes of two or more neutral 
molecular constituents bound together in the crystal lattice through non covalent 
interactions (primarily hydrogen bonding). The formation of pharmaceutical co-
crystals involves incorporation of a given active pharmaceutical ingredient with 
another pharmaceutically acceptable molecule in the crystal lattice. A 
pharmaceutical co-crystal can be designed by crystal engineering with the intention 
to improve the pure solid-state properties of an active pharmaceutical ingredient 
without affecting its intrinsic structure. Crystal engineering affords a paradigm for 
rapid development of pharmaceutical co-crystals. It can be defined as an 
application of the concepts of supramolecular chemistry to the solid state with 
particular emphasis upon the idea that crystalline solids are actual manifestations of 
self-assembly [25, 26]. 
 
Co-crystals are constructed from intermolecular interactions such as hydrogen 
bonding contact forces, and hydrogen bonding [27].The term supramolecular 
synthon is frequently used in the research field of co-crystals. It is defined as 
structural units within supramolecules which can be formed and/or assembled by 
known conceivable synthetic operations involving intermolecular interactions. 
Supramolecular synthons are spatial arrangements of intermolecular interactions 
and the overall goal of crystal engineering is therefore to recognize and design 
synthons that are robust enough to be interchanged between network structures.  
 
A pharmaceutical co-crystal is simply a co-crystal in which at least one of the 
molecular components is an active pharmaceutical ingredient (API) in conjunction 
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with another type of molecule termed a co-crystal former. More strictly, in order to 
be useful, the non-API component should be non-toxic with no adverse side effects. 
Interest in pharmaceutical co-crystals arises from the fact that, as different crystal 
forms to the pure API, they dramatically expand the range of solid forms available 
for formulation. Co-crystals have different physical properties such as habit, bulk 
density, and solubility; compressibility, friability, melting point, hygroscopy and 
dissolution rate. Formation of a co-crystal often offers scope to transform an 
amorphous or hard to crystallize active pharmaceutical ingredient into a readily 
handled, stable crystalline solid. Indeed, it is far more likely to be poor 
biopharmaceutical characteristics rather than toxicity or lack of efficacy that 
prevent a candidate active compound progressing in clinical trials  
[28,29].Discovery or design of a new, useful co-crystal solid form also offers new 
opportunities for the exploitation of intellectual property, the most common supra 
molecular synthons utilized in pharmaceutical co-crystals are shown in Fig.8 , the 
circled co-crystal design is the expected model in my co-crystal paradigm  
 
 
 
Figure 8 Typical hydrogen bonds utilized in crystal engineering [28] 
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The salycilic acid structure is composed of dimeric units through hydrogen 
bonding as expected with more hydrogen bonding from the hydroxyl group 
with the carboxylate of the same molecule, as shown in figure 9, [30]. While 
in lactic acid, the hydrogen bonding between the different molecules is 
between the hydroxyl groups of one molecule with the carbonyl of the 
adjacent molecule forming cyclic arrangement composed of six lactic acid 
molecules as shown in figure 10, [31] 
 
 
Figure 9 Salicylic acid crystal structures in solution [30] 
 
 
Figure 10 Lactic acid crystal structures in solution [31] 
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1.6 Salicylic acid and Lactic acid chemical structures: 
 
Salicylic acid is the main therapeutic compound in the proposed drug which is used 
for a number of different skin conditions caused by thickened, hard skin, such as 
warts, verrucas, psoriasis, scaly skin conditions and some nail infections. It is a 
keratolytic, which means that it works by softening the outer layer of your skin 
allowing it to loosen and shed [32]. While Lactic acid used to severe forms of dry 
scaly skin since it is a humectants and supporter. Exactly how it works is unknown 
but it increases the amount of water in the skin, making it softer and more pliable 
[33]. Salicylic acid is generally the most prominent ketrolytic compound in the 
medication product and lactic acid is the booster ketrolytic (humectants) in the 
medication product [34]. 
 
 
The following are chemical structures for salicylic acid and lactic acid [32, 33] 
respectively. 
 
 
Figure 11 Salicylic acid chemical structure 
(2-hydroxy benzoic acid) 
Figure 12  Lactic acid chemical structure 
(2-hydroxypropanoic acid) 
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2.  Literature Review: 
 
The topical microemulsion therapeutic products are of an important drug delivery 
systems and their use in therapy is becoming more widespread. Topical 
formulations to treat ailments have existed since ancient times. The purpose of 
topical dosage forms is to conveniently deliver drugs to a localized area of the skin. 
Although microemulsions can be used to deliver drugs via several routes, these 
multi use microemulsions have been extensively studied as vehicles for topical 
administration. Their composition and structure enables them to incorporate greater 
amount of drug than other topical formulations such as ointments, creams, gels and 
lotions. Delivery of drugs using these microemulsions through skin increases the 
local/systemic delivery of the drug by different mechanisms that make them 
suitable vehicles for the delivery of Antifungal [35]. 
 
Salicylic acid is a gentle acid derived from the bark of the willow tree, which has 
long been used as a traditional treatment for pain, inflammation and fever. Salicylic 
acid in ancient times was used by the ancient Greeks in about 500 BC [36]. 
Because pharmacists, chemists, and doctors were already familiar with salicylic 
acid‟s anti-inflammatory and pain-relieving properties, they sought to create a 
widely usable version of the drug. Salicylic acid has been described as a β-hydroxy 
acid and classified as a phenolic aromatic acid. The hydroxyl group of true β-
hydroxy acids is neutral, and not acidic. Salicylic acid has a pKa of 2.98. To obtain 
a significant exfoliative effect, salicylic acid must be formulated at a proper pH 
close to the pka to allow enough free acid to be present, to give significantly more 
exfoliation than formulations at any pH significantly greater than the pKa [13]. 
 
While Lactic acid was discovered in 1780 by Swedish chemist, Carl Wilhelm 
Scheele, who isolated the lactic acid from sour milk as impure brown syrup and 
gave it a name based on its origins. Lactic acid is produced by the fermentation of 
sugar and water or by chemical process and is commercially usually sold as a 
liquid. Pure and anhydrous racemic lactic acid is a white crystalline solid with a 
low melting point. Lactic acid is the biological isomer as it is naturally present in 
the human body. The greatest benefit of having a professional lactic acid peel is 
that it is gentler on your skin than most other types of peels [37]. 
 
Microemulsion emulsifying, Oxidative stability and the properties of prepared 
topical therapeutic drug based on salicylic acid and lactic acid with chemical 
emulsifiers (surfactants) and with a co-surfactant addition have been studied [9]. 
The primary use of surfactant is to lower the interfacial tension to a very small 
value which will facilitates dispersion process during the preparation of the 
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microemulsion and provide a flexible film that can readily deform around the 
droplets and be of the appropriate lipophilic character to provide the correct 
curvature at the interfacial region. The tested chemical nonionic surfactants (Tween 
20, 40, 80 and Span 20, 60) and results have shown that stable topical 
microemulsions can be obtained with the aid of co-surfactant addition. The short to 
medium chain alcohols are generally considered as co-surfactants in the 
microemulsion system. The presence of surfactant and co-surfactant in the system 
makes the interfacial tension very low. Therefore the microemulsions form 
spontaneously, with a small droplet diameter. The nonionic surfactants appeared to 
be more suitable surfactants as it was predicted by the HLB theory, these 
components can be used both for their antioxidant and their emulsifying properties 
[9]. 
 
As known, one of the major properties of salicylic acid is its ability to remove skin 
cells of the most upper layer of the skin, the stratum corneum. This keratolytic 
effect is dependent on the concentration of salicylic acid used in. For example, at a 
concentration of 10 - 15% salicylic acid shows a keratolytic effect already after 2 or 
3 days. At 5% and 1% desquamation of skin cells is seen after 7 and 10 days, 
respectively. Hence, salicylic acid is widely used as major ingredient for peelings 
or other exfoliant or abrasive skin treatments. Such peeling products contain 
salicylic acid usually at concentrations between 0.5 - 3%. Whereas the upper limit 
of 20% of is applied only in dermatological (prescription) products, the use of 
salicylic acid at this level has also been recommended for face masks. For anti-
warts products salicylic acid is usually used between 12 - 40%. Besides removing 
old cells and horny debris from the skin, keratolysis has also the advantage that it 
facilitates the penetration of other active ingredients into the skin. Salicylic acid is 
therefore often added to skin care products that contain active ingredients in order 
to increase their absorption and efficacy [36]. 
 
Many alpha-hydroxy acid (lactic acid) products, containing low- or high-acid 
concentrations, are being used. It is not known whether different products perform 
differently or whether they modulate changes in both the epidermis and dermis. 
The purpose was to examine whether treatment with 5% and 12% lactic acid 
produces different cosmetic results and produces changes in the epidermis and 
dermis [38]. Test participants applied either 5% or 12% lactic acid twice a day for 3 
months. Changes in skin smoothness and texture, the depth and number of lines and 
wrinkles, and epidermal and dermal firmness and thickness were determined. 
Treatment with 12% lactic acid resulted in increased epidermal and dermal 
firmness and thickness and clinical improvement in skin smoothness and in the 
appearance of lines and wrinkles. No dermal changes were observed after treatment 
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with 5% lactic acid; however, similar clinical and epidermal changes were noted. 
The results demonstrate that cosmetic benefits from the use of alpha-hydroxy acids 
are caused by modification of the skin surface, the epidermis and the dermis. 
Although 5% lactic acid modulates surface and epidermal changes, 12% lactic acid 
influences both the epidermis and the dermis [39]. 
 
Microemulsions are clear, thermodynamically stable systems. They were used to 
solubilize drugs and to improve topical drug availability. Salicylic acid is a 
keratolytic agent used in topical products with antimicrobial actions. The objective 
of their work was to prepare and evaluate salicylic acid microemulsion systems. 
Different concentrations of salicylic acid were prepared: S2%, S5%, and S10% which 
contain 2%, 5%, and 10% of salicylic acid, respectively. Stability study for 
6 months under ambient conditions was carried out for S10%. No remarkable 
changes were recorded except a decrease in the viscosity value after 1 month. The 
results suggested that microemulsion could be a suitable vehicle for topical 
application of different concentrations of salicylic acid [40]. 
 
 Salicylic acid has bacteriostatic and fungicidal actions as well as keratolytic 
properties. Its effectiveness for topical treatment of hyperkeratotic skin lesions is 
based on mild keratolytic action which produces slow and painless destruction of 
the epithelium. In the treatment of warts, a mild irritant reaction, which may render 
the virus more prone to immunologic stimulation or response, may add to the 
mechanical removal of infected cells [41]. Salactol contains 16.7% salicylic acid 
and 16.7% lactic acid in flexible collodion. The bioavailability of salicylic acid is 
reduced as the collodion film dries on the skin due to entrapment of the drug which 
inhibits release. The addition of lactic acid to salicylic acid collodion provides more 
efficient release of the salicylic acid, since the non volatile lactic acid remains in 
the film, thus permitting continued release of the keratolytic which may otherwise 
be entrapped within the dried collodion film. Systemic absorption of salicylic acid 
or lactic acid after application to small circumscribed areas is exceedingly unlikely 
[42]. 
 
Salatac Gel presents 12% salicylic acid and 4% lactic acid in an evaporative 
collodion-like gel which forms a cohesive and adhesive film on the skin. This 
minimizes the spread of the preparation onto the surrounding healthy skin. The gel 
quickly forms a surface film, well before it dries  completely, thereby prolonging 
the period during which the keratolytic solution can properly infiltrate and achieve 
intimate contact with the surface layers of the thickened stratum corneum. It is used 
for the topical treatment of warts, verrucas, corns and calluses [20, 43]. 
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Pharmaceutical co-crystals are emerging as a new class of solid drugs with 
improved physicochemical properties, which has attracted increased interests from 
both industrial and academic researchers. They are attractive to pharmaceutical 
scientists because they can significantly diversify the number of crystal forms that 
exist for a particular active pharmaceutical ingredient (API), and they can lead to 
improvements in physical properties of clinical relevance. Co-crystals not only 
provide a technique for improvement of physiochemical property! but also provide 
opportunity to the researchers of pharmaceutical companies regarding intellectual 
property. Co-crystal approach especially used to enhance the specific properties of 
pharmaceutical solids such as dissolution rate of poorly water soluble API and the 
physical stability of moisture liable APIs [28]. 
 
Solubility is essential for the therapeutic effectiveness of the drug, independent of 
the route of administration. Poorly soluble drugs are often a challenging task for 
formulators in the industry. Conventional approaches for enhancement of solubility 
have limited applicability, especially when the drugs are poorly soluble 
simultaneously in aqueous and in non-aqueous media. Solubilization may be 
affected by co-solvent water interaction, micellar solubilization, reduction in 
particle size, inclusion complexes, solid dispersion, and change in polymorph. 
Some new technologies are also available to increase the solubility like 
microemulsion, self emulsifying drug delivery system and supercritical fluid 
technology. This review focuses on the recent techniques of solubilization for the 
attainment of effective absorption and improved bioavailability [44]. 
 
A review on pharmaceutical co-crystals, nutraceutical co-crystals and 
pharmaceutical co-crystal polymorphs depicting their relevance both in academia 
and pharmaceutical industry because of their potential as new solid forms of the 
active pharmaceutical ingredient. The over view of crystal engineering to design 
co-crystals for altered and improved physicochemical properties such as solubility, 
dissolution rate, bioavailability, hygroscopicity etc. [45]. 
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3. Problem:  
 
Microemulsions were used in several fields as routs of administration; this sample 
application, which delivered the drug in sustained or controlled manner and 
prolonged delivery as compared to conventional dosage form for topical 
applications which exhibit minimal systemic absorption. Microemulsion can be 
prepared using a low-energy emulsification method, depending on the phase 
behavior and properties of the constituents, to promote the formation of high small 
droplets using co-surfactants that include self emulsification. So, why not using? 
the low energy technique in our medicine factories?, and introduce the new 
nanotechnology in Palestinian medicine factories as seen in all over the world in 
general using the phase behavior and studying its available applications for the 
topical treatment of warts, verrucas, corns and calluses. Why not enhancing the 
solubility of poor water soluble pharmaceutical drugs? The crystal engineering and 
super molecular chemistry were used in co-crystal formation, to improve the active 
pharmaceutical ingredients solubility as well as their bioavailability to and through 
the skin. 
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4. Research objectives: 
 
The objective of this research is to study the stability and phase behavior of 
Salicylic acid and lactic acid in a therapeutic product, in order to formulate a stable, 
biocompatible microemulsion between Salicylic acid, Lactic acid and a 
sugar/nonionic surfactant like tween 80 as well as a co-solvent such as ethanol, 
propylene glycol and water. This microemulsion could be used in the formulation 
of topical or in other routs of pharmaceutical administrations or products, 
depending on the results that will be obtained from the pseudo ternary phase 
diagram. The secondary objective is to prepare salicylic acid and lactic acid co-
crystal using co solvents in crystal engineering techniques. In which the crystal 
engineering is the design of molecular solid state structures with desired properties, 
based on intermolecular interactions. The two main intermolecular interactions are 
based on hydrogen bonding and coordination complexation.  
 
To obtain this formula there are specific objectives needed to be achieved: 
 
 To estimate phase diagram of the best components concentration for 
microemulsion preparation. 
 
 To assess the patient's satisfaction with a topical microemulsion treatment, by 
addressing the affected area of the skin very effectively. 
 
 To determine the surfactant ratios which have highly solublization capacity as 
well as highly surfactant efficiency? 
 
 To determine the water and ethanol ratios which have high solublization 
capacity as well as high efficiency? 
 
 To identify, approve and justify the output results: by dynamic light scattering, 
crossed polarizers and polarizing microscope. 
 
 To prepare and characterize co-crystals of salicylic acid and lactic acid  (API) 
in order to improve bioavailability and efficacy as an antifungal drug.  
 
 To use the following instruments in identifying the co-crystal output: FTIR, 
melting point apparatus, X-ray diffraction, 
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5. Hypothesis: 
   
There have been several topical microemulsion therapeutic products and their 
affectivity on the skin diseases as a route of drug administration without affecting 
the interior human body by any side effect even they are. Depending on these 
studies, it is expected that Palestinian Pharmaceutical Company to be entered this 
production field by a colloidal microemulsion product using the low energy 
technique, since they have a significant therapeutic activity. Additionally, have 
shown that salicylic acid and lactic acid pharmaceutical ingredients are used in the 
formulation of microemulsions to help clear and prevent pimples and skin 
blemishes in people who have acne, also used to treat skin conditions that involve 
scaling or overgrowth of skin cells such as psoriasis, scaly patches, ichthyoses, 
dandruff, corns, calluses, and warts on the hands or feet [46]. 
 
A pharmaceutical co-crystal can be designed by crystal engineering with the 
intention to improve the solid state properties of an active pharmaceutical 
ingredient without affecting its intrinsic structure. Crystal engineering affords a 
paradigm for rapid development of pharmaceutical co-crystals. Therefore crystal 
engineering was applied to increase the Bioavailability of salicylic acid and lactic 
acid by merging them in one co-crystal solid product. [47]. 
 
 
24 
 
 
 
 
Chapter Three 
 
 Instrumentation and Methodology 
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6. Instrumentation & Methodology: 
 
6.1 Instrumentation: 
 
Analytical balance (Precisa 125-A) , Vortex (VELP), culture tubes sealed with 
Viton lined screw caps, Incubators (WTB Binder), crossed polarizers, polarizer 
microscope and Dynamic light scattering, reflux unit apparatus, glass wares, FTIR 
(AVATAR 320), Melting point apparatus (BUCHI B-545), X-ray diffraction,  
 
6.2 Materials: 
 
Salicylic acid 100% (Rhodia), Lactic acid 90% (Merck), ethanol 96% (shitzer), 
methanol (J.T.Baker), diethyl ether (Merck), acetonitrile (J.T.Baker), polysorbate 
80 or Tween 80 (Eigenmann & Veronelli), purified water, castor oil (gustavheess) 
and propylene glycol (Dow). All components were used as supplied and tested in 
Beit Jala Pharmaceutical Company for further purification. 
 
6.3 Phase diagram Methodology:  
 
6.3.1 Dissolution of Salicylic acid and Lactic acid 
 
Salicylic acid is an organic soluble (ethanol) while lactic acid is an aqueous (water) 
and organic (ethanol) miscible, therefore it was suggested to use the minimum 
amount of ethanol that is able to dissolve them in a solution (to enhance the drugs 
release). Salicylic acid and lactic acid solution (Ethanolic solution ) 
 
6.3.2 Constructing of Phase Diagram: 
 
The phase behavior of the systems consisting of water (with or without Co-solvent 
(propylene glycol)), castor oil (with or without Ethanolic solution), surfactant 
(Tween 80) may be described on a phase tetrahedron whose apexes respectively 
represent the pure components.1g mixture consisting of Ethanolic solution (with or 
without castor oil) and surfactant (Tween 80) at different weight ratios were 
prepared in culture tubes sealed with Viton lined screw caps and stirred by vortex 
until clear solution was obtained. See table below for each phase diagram tube 
components. These samples were titrated with water (with or without Co-solvent 
(propylene glycol)) which was added drop wise until its solubilization limit was 
reached. See table below for each titration percentage required amount. Vigorous 
stirring followed after additions on a vortex mixer. The time for equilibration 
between each addition was typically, from a few minutes up to 24 hours (therefore 
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the reading will be taken after 24 hours). Each phase diagram was investigated at 
three temperatures 25, 37and 45°C and detecting the number of phase by bare eye, 
the anisotropy by cross polarizer. The single isotropic sample which will be dark 
under cross polarizer will be regarded to either cubic or micelle; which can be 
distinguished by its viscosity. The anisotropic lamellar liquid crystal and hexagonal 
liquid crystal are determined by the cross polarizer and polarizing microscope. 
Detect the boundary of single phase; four phase diagrams were installed and each 
phase was tested at three temperatures 25, 37and 45°C.  Finally draw the phase 
diagram using specified computer software. 
 
Oil+ Ethanolic solution  
 
Water                                         Tween 80 
Figure 13 Phase Diagram 1 Proposed 
constructions 
 
 
 
 Ethanolic solution  
 
Water                                         Tween 80 
Figure 14 Phase Diagram 2 Proposed 
constructions 
 
   
Ethanolic solution 
 
Water+PG                                 Tween 80 
Figure 15 Phase Diagram 3 Proposed 
constructions 
 
         Oil+ Ethanolic solution 
 
Water+PG                                    Tween 80 
Figure 16 Phase Diagram 4 Proposed 
constructions 
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Tube components amount for each phase diagram: 
 
Table 1 Phase diagram 1 components Table 2 Phase diagram 2 components 
 
Tube 
code# 
Surfactant 
(g) ---(B) 
Oil+EtOH 
(g) --- ( C ) 
100% (C) --------- 0.9998 
0.5,9.5 0.0499 0.9501 
19 0.1004 0.9005 
28 0.2002 0.8003 
37 0.2999 0.7002 
46 0.4002 0.5995 
55 0.4992 0.5004 
64 0.6003 0.3998 
73 0.7002 0.3002 
82 0.7997 0.2004 
91 0.8998 0.1010 
9.5,0.5 0.9499 0.0495 
100 % (B) 0.9996 --------- 
 
 
Tube 
code# 
Surfactant 
(g) ---(B) 
EtOH 
(g) --- ( C ) 
100% (C) --------- 1.0003 
0.5,9.5 0.0505 0.9501 
19 0.1000 0.9003 
28 0.2008 0.8007 
37 0.3006 0.6996 
46 0.3995 0.6003 
55 0.5004 0.4996 
64 0.5997 0.4004 
73 0.7000 0.2997 
82 0.7996 0.2005 
91 0.9002 0.1005 
9.5,0.5 0.9498 0.0498 
100 % (B) 1.0003 --------- 
 
Table 3 Phase diagram 3 components Table 4 Phase diagram 4 components 
 
Tube 
code# 
Surfactant 
(g) ---(B) 
Oil+EtOH 
(g) --- ( C ) 
100% (C) --------- 1.0003 
0.5,9.5 0.0503 0.9499 
19 0.1003 0.9005 
28 0.1997 0.7999 
37 0.3002 0.7003 
46 0.4000 0.5998 
55 0.5004 0.5004 
64 0.5997 0.4002 
73 0.7002 0.2997 
82 0.8005 0.2002 
91 0.8998 0.0997 
9.5,0.5 0.9498 0.0501 
100 % (B) 1.0002 --------- 
 
 
Tube 
code# 
Surfactant 
(g) ---(B) 
Oil+EtOH 
(g) --- ( C ) 
100% (C) --------- 0.9997 
0.5,9.5 0.0496 0.9498 
19 0.0997 0.9000 
28 0.2001 0.8000 
37 0.3005 0.7004 
46 0.4000 0.5998 
55 0.4997 0.4998 
64 0.6002 0.3999 
73 0.6996 0.3005 
82 0.8002 0.1999 
91 0.9000 0.0997 
9.5,0.5 0.9497 0.0502 
100 % (B) 0.9999 --------- 
 
Note: The tube code refers to the amount of surfactant and oil components in each 
tube. For example tube code # 19 contains 0.1g of surfactant and 0.9g of oil 
component phase. 
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Titration amount required in grams for each percentage addition: 
 
Table 5 Titration percentage versus weight 
 
% 
Total added 
weight 
(g) 
Net weight 
Each interval 
(g) 
4 0.0417 0.0417 
8 0.0870 0.0453 
12 0.1364 0.0494 
16 0.1905 0.0541 
20 0.2500 0.0595 
24 0.3158 0.0658 
28 0.3889 0.0732 
32 0.4706 0.0817 
36 0.5625 0.0919 
40 0.6667 0.1042 
44 0.7857 0.1191 
48 0.9231 0.1374 
52 1.0833 0.1603 
56 1.2727 0.1894 
60 1.5000 0.2273 
64 1.7778 0.2278 
68 2.125 0.3472 
72 2.5714 0.4464 
76 3.1667 0.5953 
80 4.0000 0.8333 
84 5.2500 1.2070 
88 7.3330 2.0833 
92 11.500 4.1667 
96 24.000 12.580 
 
 
 
The total added Weight (g) can be calculated as the term x from the following 
equation:    #% * (1+x) = x* 100    
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6.4 Co-crystallization methodology: 
Salicylic acid and Lactic acid that are proposed as active pharmaceutical 
ingredients (API‟s) in this project, they are used as ketrolytic compounds. The 
proposed solvents were Ethanol, Methanol, Diethyl ether and Acetonitrile to be 
used for the co-crystal formation each one in both co-crystal techniques (solution 
and Grinding). Currently the most established methods for co-crystal formation are 
reflux solution and mechanical techniques. In reflux co-crystal synthesis, 
stoichiometric ratios of active pharmaceutical ingredients (API‟s) are dissolved in a 
solvent of choice and super saturation is achieved either through a temperature 
difference or through evaporation of the solvent. 
6.4.1 Reflux Co-crystallization technique: 
API‟s target concentration expected to be formulated were mixed with 10 ml of the 
selected solvent in a round bottom flask and refluxed for 2.5 hours. Collecting the 
reflux solution in a capped glass ware and loosen the cap screw slightly or making 
holes in the top part of the cap, allowed to stand for several days (14-21 day). Co-
crystals were obtained in each solvent, in which the physicochemical properties are 
notified and tested. 
 
                         Table 6 salicylic acid and lactic acid target concentrations 
 Salicylic acid and Lactic acid (2:1) molar ratio 
Target 
Concentration % 
Solvent Salicylic acid (g) Lactic acid (g) 
100% Ethanol 1.1998 0.4468 
100% Methanol 1.2001 0.4428 
100% Diethyl ether 1.2004 0.4440 
100% Acetonitrile 1.2004 0.4440 
 
A new reflux drug concentration is done according to the reflux technique for more 
co-crystal clarifications, by means of duplication the lactic acid molar ratio 
concentration and fixing the salicylic acid molar ratio. API‟s new target 
concentration expected to be formulated were mixed with 10 ml of the selected 
solvent in a round bottom flask and refluxed for 2.5 hours. Collecting the reflux 
solution in a capped glass ware and loosen the cap screw slightly or making holes 
in the top part of the cap, allowed to stand for several days (30-40 day). Co-crystals 
were obtained in each solvent, in which the physicochemical properties are notified 
and tested. 
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                 Table 7 salicylic acid and lactic acid concentrations 
 Salicylic acid and Lactic acid (2:2) molar ratio 
Target 
Concentration % 
Solvent Salicylic acid (g) Lactic acid (g) 
 
100% Ethanol 2.3997 1.7796 
 
100% Methanol 2.4005 1.7786 
 
100% Acetonitrile 2.4011 1.7767 
 
6.4.2 Grinding (mechanical) Co-crystallization technique: 
There have been great progresses in co-crystal formation via grinding method over 
the past few years. There are different techniques for co-crystal formation via 
grinding. Stoichiometric ratios of active pharmaceutical ingredients (API‟s) are 
mechanically agitated (e.g. by grinding in a mill) to induce phase transformations 
from a physical mixture into co-crystal. Drops of solvent, which are considered as 
plasticizers, have been shown to impact the crystallization outcome.  
Mechanical methods are often favored due to their speed, procedural simplicity, 
and potential for green chemistry. These two methods were largely successful in 
the discovery of co-crystals. 
The grinding method was applied on different molar ratios for each solvent chosen, 
depending on the accuracy and linearity tests of active pharmaceutical ingredients 
(API‟s) in the pharmaceutical validation procedure 50%, 75%, 100%, 125% and 
150 % of the target concentration dose. By fixing one active pharmaceutical 
ingredient (API) concentration and making the variations with the other, as listed in 
the following table: 
31 
 
 
              Table 8 Salicylic acid and Lactic acid variable molar ratios / grinding co-crystallization technique 
 Variable Salicylic acid and 
constant Lactic acid  
Constant Salicylic acid and 
Variable Lactic acid  
Concentration 
% 
Tube 
# 
Salicylic 
acid (g) 
Lactic 
acid (g) 
Tube 
# 
Salicylic 
acid (g) 
Lactic 
acid (g) 
 
50% 1 0.06 0.0444 1 0.12 0.0222 
       
75% 2 0.09 0.0444 2 0.12 0.0333 
 
100% 3 0.12 0.0444 3 0.12 0.0444 
 
125% 4 0.15 0.0444 4 0.12 0.0555 
 
150% 5 0.18 0.0444 5 0.12 0.0666 
 
This procedure was applied for the four solvents chosen and each solvent for ten 
different molar ratios. 
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Chapter Four 
 
 Results And Discussion 
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7. Results and Discussions: 
 
7.1 Microemulsion phase diagram results: 
 
7.1.1 Pseudo ternary phase diagram 1 Tween 80 in the corner B and Castor 
oil with Ethanolic solution (1:1) in the corner C demonstrates that the 
microemulsion was obtained and started as a single clear, isotropic and not shiny 
solution upon the addition of the first 4% water to the system in the tube number 46 
which contains 0.4g B and 0.6g C at 25, 37 and 45°C, up to tube 100%B. The 
microemulsion region remains the same with increasing the temperature, which 
refers to the fact that the non-ionic surfactant used is soluble in water, while it is 
soluble in castor oil with the aid of ethanol in a specific ratio. Since castor oil is 
insoluble in water, therefore ethanol is used as a tuning parameter for all 
ingredients and contributes clearly in forming the microemulsion for tube 46 up to 
100% B. Thus, an increase in the temperature will not have an effect on the non-
ionic surfactant micelle structure (W/O). As shown in the bellow pseudo ternary 
phase diagram at all studied temperature conditions. 
Castor oil +Ethanolic solution
Water Tween 80
Figure 17 Pseudo ternary phase diagram 1 
 Where: Ethanolic solution is 12.0g of Salicylic acid and 4.44g of Lactic acid in 50ml of ethanol (96%) 
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7.1.2 Pseudo ternary phase diagram 2,Tween 80 in the corner B and Ethanolic 
solution in the corner C demonstrates that the microemulsion was obtained and 
started as a single clear isotropic and not shiny solution upon the addition of 4% 
water to the system in a wide region from 100%C up to 100%B tubes at 25, 37 and 
45°C with a different viscosity that is increased with increasing the surfactant 
concentration. The microemulsion region remains the same with increasing the 
temperature, which refers to the fact that the non-ionic surfactant used is soluble in 
water and in ethanol in a wide ratio, in which ethanol is used as a tuning parameter 
for all ingredients and ethanol is soluble and miscible in water by nature 
knowledge. Thus, an increase in the temperature will not have an effect on the non-
ionic surfactant micelle structure (W/O), and the absence of castor oil increases the 
non-ionic surfactant solubility region as shown in the bellow pseudo ternary phase 
diagram at all studied temperature conditions. 
Tween 80Water
Ethanolic solution
Figure 18 Pseudo ternary phase diagram 2 
 
Where: Ethanolic solution is 12.0g of Salicylic acid and 4.44g of Lactic acid in 50ml of ethanol (96%) 
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7.1.3 Pseudo ternary phase diagram 3, Tween 80 in the corner B and 
Ethanolic solution in the corner C demonstrates that the microemulsion was 
obtained and started as a single clear isotropic and not shiny solution upon the 
addition of 4% water and propylene glycol (1:1) to the system in a wide region 
from 100%C up to 100%B tubes at 25, 37 and 45°C with a different viscosity 
which is increased with increasing the surfactant concentration. The microemulsion 
region remains the same with increasing the temperature, which refers to the fact 
that the non-ionic surfactant used is soluble in water and also in the propylene 
glycol used as co-surfactant, which shares the non-ionic surfactant in making a 
smallest droplet size to form this wide microemuslion region.  Also ethanol is used 
as a tuning parameter and co-solvent for all ingredients. The non-ionic surfactant is 
water and ethanol soluble, therefore, an increase in the temperature will not have an 
effect on the non-ionic surfactant micelle structure (W/O) or (O/W) . As shown in 
the bellow pseudo ternary phase diagram at all studied temperature conditions. 
Ethanolic solution
Water+ PG Tween 80
 
Figure 19 Pseudo ternary phase diagram 3 
 
Where: Ethanolic solution is 12.0g of Salicylic acid and  4444 g of Lactic acid in 50ml of ethanol (96%) 
36 
 
7.1.4 Pseudo phase diagram 4, Tween 80 in the corner B and Castor oil with 
Ethanolic solution (1:1) in the corner C demonstrates that the microemulsion was 
obtained and started as a single clear isotropic and not shiny solution upon the 
addition of 4% water and propylene glycol (1:1) to the system in the tube 100%C 
up to 100%B tubes at 25, 37 and 45°C with a different microemulsion viscosity that 
is increased with increasing the surfactant concentration. The microemulsion region 
remains the same with increasing the temperature, which refers to the fact that the 
non-ionic surfactant used is soluble in water, and also in the propylene glycol used 
as co-surfactant, which shares the non-ionic surfactant in making a smallest droplet 
size to form this microemuslion region.  Castor oil is insoluble in water but the 
presence of propylene glycol shares with 4% solubility region near the corner C, 
and with increasing the surfactant concentration the microemulsion region becomes 
larger up to 100% B concentration with the aid of ethanol in a specific ratio, in 
which ethanol is used as a tuning parameter for all ingredients. Thus, an increase in 
the temperature will not have an effect on the non-ionic surfactant micelle structure 
(W/O). As shown in the bellow pseudo ternary phase diagram at all studied 
temperature conditions. 
Water+PG Tween 80
Castor oil + Ethanolic solution
 
Figure 20 Pseudo ternary phase diagram 4 
Where: Ethanolic solution is 12.0g of Salicylic acid and  4444 g of Lactic acid in 50ml of ethanol (96)
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7.2 Co-crystal results: 
 
7.2.1 Reflux Co-crystallization technique: 
 
The co-crystals obtained from each solvent used in the reflux co-crystal technique 
were amazing and impressive in their uniformity, physicochemichal properties, 
shape and their order of formation. See the photo pictures bellow for the pure active 
pharmaceutical ingredient and the co-crystal paradigm obtained in each selected 
solvent.  
Salicylic acid (pure) Lactic acid (pure) 
 
 
 
 
 
Ethanol 
Co-crystal 
Methanol 
Co-crystal 
Diethyl ether 
Co-crystal 
Acetonitrile 
Co-crystal 
 
 
 
 
 
 
 
 
Figure 21 Co-crystals obtained from each co-solvent / Reflux technique 
 
Note: Diethyl ether Co-crystals seems white in its color due to the co solvent effect of drying, while when 
they are wet they behave like other solvents in the physical appearance.  
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The obtained co-crystals were tested individually for their melting point and FTIR 
spectrum test. The co-crystal formation is readily apparent from the resulting 
physical properties of the new material. Formation of a co-crystal from Salicylic 
acid (white powder) and Lactic acid (viscous clear liquid) is immediately apparent 
from the transparent color of the co-crystal, despite the fact that salicylic acid is 
white solids and lactic acid is clear liquid. The color arises from the fact that the co-
crystal as part of the overall hydrogen bonded crystal packing arrangement, with 
concomitant reduction of the π- π * energy gap [48]. 
 
The data showed the initial appearance of 1.8:1 ratio for salicylic acid and lactic 
acid respectively, that the melting point is about 120˚C.In addition to the melting 
point, FTIR spectroscopy of solid samples (measured for example using KBr salt) 
can also give a characteristic fingerprint of a particular solid form. Because 
vibrational spectroscopy depends on bond vibrational modes which are only 
moderately worried by the molecule‟s solid state environment, the differences in 
FTIR spectra between pure active pharmaceutical ingredients forms, or between co-
crystal and pure forms, can be relatively major appeared. However, if particular 
bands are sensitive to solid form (e.g. when there is a significant change in 
hydrogen bonding mode in different forms) then vibrational spectra represent a 
useful and facile method of distinguishing different polymorphs and co-crystals. 
Among many recent patents relating to potential commercial co-crystal products, 
the possibility of combining two active ingredients in a single co-crystal is an 
interesting one and has been claimed in the co-crystallization. The combination 
drug has been suggested to have physical properties and biological activity that are 
distinct from the individual properties of the two components [49]. 
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The original known and tested FTIR spectrum was as followed for each pure active 
pharmaceutical ingredient: 
 
API Major peak  Pure Salicylic acid API  FTIR spectrum 
 
 
Salicylic acid  
FTIR major peak  
Figure 22 pure Salicylic acid FTIR spectrum 
 
API Major peak  Pure Lactic acid API FTIR spectrum                    
  
 
 
 
 
Lactic acid 
FTIR Major peak 
 
 Figure 23 Pure Lactic acid FTIR spectrum 
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7.2.2 Grinding (mechanical) Co-crystal technique 
 
The co-crystals obtained from each co-solvent used in the grinding mechanical co-
crystal technique were amazing in their uniformity, shape and their order of 
formation. See the photo pictures bellow for each  
 
Ethanol co-solvent Methanol co-solvent 
 
 
 
 
 
 
 
 
Diethyl ether co-solvent Acetonitrile co-solvent 
 
 
 
 
 
 
 
 
Figure 24 Co-crystal obtained from each co-solvent / grinding technique 
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The obtained co crystals from Grinding (mechanical) Co-crystal technique were 
tested individually for FTIR spectroscopy of solid samples using KBr salt and 
compared with the pure samples spectrum that was tested before at the beginning.  
  Table 9 Grinding co-crystallization technique FTIR results 
Solvent 
Constant Salicylic 
acid and Variable 
Lactic acid 
Variable Salicylic 
acid and Constant  
Lactic acid 
E
th
a
n
o
l 
co
-s
o
lv
en
t 
Tube # Result Tube # Result 
1 Positive 1 Positive 
2 Positive 2 Positive 
3 Positive 3 Positive 
4 Positive 4 Positive 
5 Positive 5 Positive 
 
M
et
h
a
n
o
l 
co
-s
o
lv
en
t 
Tube # Result Tube # Result 
1 Negative 1 Positive 
2 Negative 2 Positive 
3 Partial 3 Positive 
4 Positive 4 Positive 
5 Positive 5 Positive 
 
D
ie
th
y
l 
et
h
er
 
co
-s
o
lv
en
t 
Tube # Result Tube # Result 
1 Positive 1 Positive 
2 Positive 2 Positive 
3 Positive 3 Positive 
4 Positive 4 Positive 
5 Positive 5 Positive 
 
A
ce
to
n
it
ri
le
 
co
-s
o
lv
en
t 
Tube # Result Tube # Result 
1 Negative 1 Positive 
2 Negative 2 Positive 
3 Positive 3 Positive 
4 Positive 4 Negative 
5 Positive 5 Negative 
Note:  -    Negative means no co-crystal obtained 
- Partial means weak co-crystal obtained, expected to negative results 
- Positive means a clear repeatable co-crystal obtained 
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The obtained co-crystal paradigm FTIR spectrum in diethyl ether as co-solvent: 
FTIR spectrum for the obtained co-crystals paradigm in Diethyl ether as a 
co-solvent according to the grinding technique 
 
 
 
 
 
 
 
Co-crystal paradigm major peaks 
 
 
Figure 25 Co-crystal obtained from diethyl ether FTIR spectrum / grinding technique 
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The co-crystals obtained either from reflux or grinding techniques were tested 
using FTIR showing an impressive merged active pharmaceutical ingredient. By 
comparing the major peaks obtained with those in the pure API‟s spectrums, the 
following table will show how many wave lengths shifted in the co-crystal 
spectrums: 
Table 10 Wave length degree shift in cm
-1
 for the major  peaks 
Solvent 
Constant Salicylic acid and 
Variable Lactic acid 
Variable Salicylic acid and 
Constant  Lactic acid 
 Wave number  degree shift in cm
-1
 
for major peaks 
Wave number  degree shift in cm
-1
 
for major peaks 
 
E
th
a
n
o
l 
co
-s
o
lv
en
t 
Tube # 3235 1735 1657 1444 1128 1046 Tube # 3235 1735 1657 1444 1128 1046 
1 +1 -3 +3 +1 +2 +2 1 +5 -3 +2 +1 +2 +1 
2 -1 -3 +4 +1 +2 +1 2 +6 -3 +2 +1 +2 +1 
3 +4 -3 +1 +1 +2 ---- 3 +4 +1 -1 +1 +2 +1 
4 +3 -3 +1 +1 +2 +1 4 +5 -3 +2 +1 +2 +1 
5 +1 -6 -2 --- --- +3 5 +2 -6 +2 --- +3 +3 
 Reflux +5 -3 +2 +2 +2 +1        
 
M
et
h
a
n
o
l 
co
-s
o
lv
en
t 
Tube # 3235 1735 1657 1444 1128 1046 Tube # 3235 1735 1657 1444 1128 1046 
1 +2 --- -1 --- --- --- 1 +8 +0.5 +3 +1 +2 +1 
2 +2 --- +2 --- --- --- 2 +4 -3 +2 +1 +3 --- 
3 +7 -3 +2 --- --- +4 3 +2 -5 +2 +1 +3 +3 
4 +7 +3 +2 +1 +3 +2 4 +5 +5 +5 +0.5 +4 +4 
5 +1 +3 +2 +1 +3 +2 5 +5 -4 +3 +0.5 +3 +3 
 Reflux +2 -3 +2 +0.5 --- +5        
 
D
ie
th
y
l 
e
th
er
 
co
-s
o
lv
en
t 
Tube # 3235 1735 1657 1444 1128 1046 Tube # 3235 1735 1657 1444 1128 1046 
1 +5 -4 +2 +1 +2 +1 1 +5 -3 +2 +1 +1 --- 
2 +4 -3 +3 +1 +1 --- 2 --- -3 +3 +1 +1 +1 
3 +4 +1 +1 +1 +1 +1 3 +4 -4 +1 +1 +2 +1 
4 +2 -6 +2 +1 --- +2 4 +6 -4 +2 +1 +1 +1 
5 +3 -5 +1 +1 +1 +1 5 +2 -7 +2 +1 +2 +1 
 Reflux +5 -4 +2 +1 +1 +1        
 
A
ce
to
n
it
ri
le
 
co
-s
o
lv
en
t 
Tube # 3235 1735 1657 1444 1128 1046 Tube # 3235 1735 1657 1444 1128 1046 
1 +3 --- -1 --- --- --- 1 --- +0.5 -1 +3 +1 +1 
2 +4 --- +1 --- --- --- 2 +5 -3 +3 +1 +1.5 +1 
3 +8 -3 +3 +1.5 +1 +0.5 3 +5 +0.5 -2 +1 +1 --- 
4 +2 -3 +3 +1 +1 +1 4 +3 --- -1 --- --- --- 
5 +3 +8 +2 +0.5 +2.5 +2 5 +2 --- +1 --- --- --- 
 Reflux +6 -3 +3 +1 +2 +1        
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7.2.3 The proposed compounds from co-crystallization paradigms expected: 
 
The figure bellow represents the expected products paradigms formed by hydrogen 
bonding due to co-solvents utilized between lactic acid and salicylic acid. 
 
O
+
CH3
OH
OH
O
OH
OH
 
 
 
 
Paradigm 1 
 
 
Paradigm 2 
 
Paradigm 3 
 
Paradigm 4 
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Paradigm 5 
 
Paradigm 6 
 
 
Paradigm 7 
 
O
H
OH
HO
O
O
OH
CH3
 
Paradigm 8 
 
 
Paradigm 9 
 
 
Paradigm 10 
 
Paradigm 11 
 
O
H
O
H
O O
 CH3
O
OH
H
 
Paradigm 12 
O
H
O
O
H
O
OH
CH3
OH
 
Paradigm 13 
O
H
O
H
O O
 CH3
O
OH
H
 
Paradigm 14 
 
Figure 26 Proposed co-crystal paradigms (1 – 14) structures 
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7.2.4 Co-crystal solubility in water: 
The general United State Pharmacopeia solubility requirements are listed in the 
following table:  
Table 11 United State Pharmacopeia solubility criteria 
Classification 
Parts of solvent required for 
one part of solute 
(between 15˚C and 25˚C) 
Very soluble  Less than 1 
Freely soluble  From 1 to 10 
Soluble  More than 10 to 30 
Sparingly soluble More than 30 to 100 
Slightly soluble  More than 100 to 1000 
Very slightly soluble More than 1000 to 10000 
Practically insoluble More than 10000 
 
It was known that salicylic acid solubility is slightly soluble in water and freely 
soluble in ethanol (96 per cent), while lactic acid solubility is miscible with water 
and with ethanol (96 per cent).  
From previous co-crystal aims mentioned before in the text, it was supposed to 
change and modify the solubility of the active pharmaceutical ingredients in the 
new paradigms obtained. The surprise is obtained after testing the co-crystal 
paradigm, in each solvent prepared previously, in water as a solubility solvent used 
and the results are: 
Sample taken from each co-crystal paradigm is about 0.5 g, an attempt to dissolve it 
in 10 ml purified water, using volumetric flask, by sonication for 15 minutes, and 
the result was not totally soluble. Then the same solution from each paradigm was 
transferred totally to 25 ml volumetric flask and diluted up to volume with purified 
water and sonicated for 15 minutes, and the result was also not totally soluble. Then 
the same solution from each paradigm was transferred totally to 50 ml volumetric 
flask and diluted up to volume with purified water and sonicated for 15 minutes, 
and the result was totally soluble.  
As a conclusion for the solubility test, since (1) salicylic acid is sparingly soluble in 
water (which means each 1.0 g powder is sparingly soluble in 30-100 ml of 
solvent), and (2) lactic acid is miscible in water (which means no problem with 
lactic acid solubility in water). Then it was found that each 0.5 g co-crystal 
paradigm is soluble in 50 ml of purified water. Therefore the solubility is modified 
in each paradigm co-crystal, which means and assures that new compound is 
formed. 
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Figure 27 Photos for sample representing co-crystal obtained from 
each co-solvent used in water, at the beginning 
 
 
Figure 28 Photos for sample representing co-crystal obtained from 
each co-solvent used in water, after sonication for 15 
minutes, few is dissolved  
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Figure 29 Photos for sample representing co-crystal obtained from each 
co-solvent used in water, after the transfere in 50ml volumetric flask  
 
 
Figure 30 Photos for sample representing co-crystal obtained from each 
co-solvent used in water, after sonication for 15 minutes. It is 
completely dissolved 
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7.2.5 The co-crystal melting point: 
 
Pure salicylic acid pharmaceutical ingredient melting point is about 159˚C, while 
lactic acid pure pharmaceutical ingredient melting point is about 53˚C. The 
expected new co-crystal paradigm melting point is to be lower than 159˚C and 
higher than 53˚C, if the paradigm obtained is succeeded as expected and yes it is, 
the following data result are for part of the co-crystals tested:  
 
 Co-crystal sample melting Range is 127.6-127.7°C 
 Co-crystal sample melting Range is 138.3-139.4°C 
 Co-crystal sample melting Range is 141.5-147.8°C 
 Co-crystal sample melting Range is 145.2-149.1°C 
 
The variation change between the co-crystal melting point ranges is dependent on 
the target active pharmaceutical concentration and depending on the molar ratio for 
each co-crystal tested. But even so, there is a clear change in the melting point 
range which will assure that a new paradigm (composed of merging the two active 
pharmaceutical ingredients) is obtained by using any of the solvents suggested 
ethanol, methanol, diethyl ether or acetonitrile. 
 
 
 
 
 
 
Note: for data results print out refer to the figures 31& 32 in the list of appendices.  
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8. Conclusion  
 
This work shows that the addition of short chain alcohol as a co-surfactant at 
different mass fraction in the dissolution of active pharmaceutical ingredients 
mixture is necessary to initiate the formation of drug product microemulsion in the 
formula of water, propylene glycol and sugar ester nonionic surfactant such as 
polysorbate 80 (Tween 80) due to temperature insensitivity of sugar ester; In 
addition, short chain alcohol is used as "tuning parameter "to increase the flexibility 
of the surfactant film. The increase of the amount of ethanol concentration supports 
w/o microemulsion to form o/w microemulsion in a wide concentration range 
within the phase diagram regions. 
 
The microemulsion  drug product was obtained in the four phase diagrams upon the 
addition of 4% water (with or without propylene glycol), in which it is isotropic, 
clear and non shinny microemulsion  at three temperatures 25, 37 and 45˚C in the 
same phase behavior at all temperature conditions and continued up to 100% 
aqueous addition, successfully.  
 
The co-crystal paradigm of salicylic acid and lactic acid was obtained clearly in the 
reflux technique for each co-solvent used, which was tested firstly using FTIR, as 
well as in the grinding technique at different molar ratios, secondly using melting 
point range. 
 
9. Future work  
The co-crystal paradigms obtained will be tested externally for determining the 
lattice structure of the new compound structure obtained, using x-ray structure 
analysis. 
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مستحلب بجزٌئبث صغٍرة جذا ًٌحتوي على حمض السبلسٍلٍك وحمض 
 اللاكتٍك, واستخذام طرٌقت البنٍت البلورٌت فً دمج الاحمبض المستخذمت
 
 إعذاد اىطبىب: ٍبٕش عبذ اىنشٌٝ ٍحَذ اىدَو4
 
 إبشإٌٞ مٞبىٜ4 اىبشفس٘س إششاف: 
 ٍششف ثبّٜ: اىذمخ٘س ٍحَذ اب٘ اىحبج4
 
 :الملخص
 
عيٚ   )lacipoT(حٖذف ٕزٓ اىذساست اىٚ ححؼٞش ٍْخح دٗائٜ ىعلاج الاٍشاع اىديذٝت اىَ٘ػعٞت 
 ل ٗحَغ اىلامخٞ dica cilycilas شنو ٍسخحيب بدضٝئبث طغٞشة ٗٝح٘ٛ حَغ اىسبىٞسٞيٞل
ىعلاج ٍْبؽق ٍعْٞت ٍِ اىديذ, بخشمٞببث ٍخخيفت ٗببسخخذاً أقو مَٞت ٍَنْت ٍِ ٍشمب  dica citcal
4 اسخخذاً اىَشمببث اىنح٘ىٞت tnatcafrus( ( 18ٗف حدبسٝبً ببسٌ حِ٘ٝ شُ ٍّ٘٘اٗىٞبث اىَعس٘سبخب
اُ ؽ٘س   مَ٘ا د ٍسبعذة ىيزٗببُ4  locylg enelyporp قظٞشة اىسيسيت ٍثو بشٗبٞيِٞ خلاٝن٘ه
ببلاػبفت 4 ٗاىط٘س اىَبئٜ اىَسخخذً ٕ٘ اىَبء اىْقٜ4 )lio rotsac( اىخشٗع اىضٝج اىَسخخذً ٕ٘ صٝج 
  cilycilasاىٚ أُ ٕزٓ اىذساست حٖذف ىخحؼٞش َّ٘رج اىنشٝسخبه اىَشخشك بِٞ حَغ اىسبىٞسٞيٞل
 مَ٘اد دٗائٞت فعبىت ببسخخذاً ٍحبىٞو شٞنت ٍخخيفت4   dica citcal ٗحَغ اىلامخٞل dica 
 
سٝب ًببسٌ فٜ ٕزا اىبحث, قَْب بذساست أثش ّسب ٍخخيفت ٍِ ٍشمب س٘سبخبُ ٍّ٘٘اٗىٞبث اىَعشٗف حدب
 dna 73 ,52(.عيىذساست اىَشحيت اىقخشحت عيٚ دسخبث حشاسة ٍخخيفت  tnatcafrus( ( 18حِ٘ٝ 
عيٚ سي٘ك اىَشحيت  )locylg enelyporp(اػبفت اىَزٝب اىششٝل قَْب ببمخشبف أثش  )C°54
 natibros(س٘سبخبُ ٍّ٘٘اٗىٞبث اىَقخشذ4 أخٞشا,ً دساست فعبىٞت سي٘ك اىَشحيت اىَقخشذ ه 
 yportosi دسخت اىحشاسة , أعطٚ ٍحي٘ه ٍسخحيب ٍ٘حذ اىخ٘اصٗبخأثٞش  )etaeloonom
 ssorc ,noitcepsni lausiv gnisu(ببسخخذاً اىعِٞ اىَدشدة,  ( ) noitulosnoislumeorciM
% ٍِ اىط٘س اىَبئٜ 4بأقو مَٞت اػبفت ٕٜٗ   )gnirettacs thgil cimanyd dna sreziralop
 4)C˚54 &C˚73 ,C˚52(ة عيٚ مو دسخبث اىحشاس
 
ببلاػبفت اىٚ أّ فٜ ٕزا اىبحث, قَْب بذساست اٍنبّٞت اسخعَبه ٍحبىٞو ششٝنت ٍخخيفت فٜ حنِ٘ٝ َّ٘رج 
اىنشٝسخبه اىششٝل , ٍثو الاٝثبّ٘ه  , اىَٞثبّ٘ه, داٛ اٝثو اٝثش ٗ اسٞخّ٘بٝخشاٝو4 ببسخخذاً حقْٞبث 
اٗحقْٞت اىطحِ ىيخشامٞض اىَقخشحت ٗىخشامٞض أخشٙ بْسب  xulfeRٍخخيفت ٍطبقت, س٘اًء مبّج حقْٞت 
4 َّ٘رج اىنشٝسخبه اىششٝل حٌ اىحظ٘ه عيٞٔ فٜ خَٞع حقْٞت اىشٝفينس بْدبخ ٗبح٘اىٜ ٍ٘ىٞت ٍخخيفت
4 حٌ فحض مو اىَْبرج ببسخخذاً اىفحض اىطٞفٜ ببلاشعت ححج ٍؤمذ % فٜ حقْٞت اىطحِ بْدبذ  18
 دسخت الاّظٖبس ٗفحض ٍذٙ  (fni mrofsnart reiruoF)ypocsortceps derarاىحَشاء  
 , ببلاػبفت ىفحض اىزائبٞت ىبعغ اىعْٞبث مَشحيت أٗىٚ ىيخحقق ( )egnar tniop gnitlem
   4ٍٗذٙ ححسْٖب ٗحط٘سٕب )ytilibulos(
55 
 
 
The following FTIR spectrums refers to all tested samples in this research either for reflux 
or grinding techniques each are ordered related to the co-solvent used;  
Appendix 1  :  
FTIR spectrums for grinding technique in diethyl ether co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
2 
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FTIR spectrums for grinding technique in diethyl ether co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
4 
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FTIR spectrums for grinding technique in diethyl ether co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
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Appendix 2 :  
FTIR spectrums for grinding technique in diethyl ether co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
2 
 
 
59 
 
 
FTIR spectrums for grinding technique in diethyl ether co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
4 
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FTIR spectrums for grinding technique in diethyl ether co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
 
 
61 
 
 
Appendix 3 :  
FTIR spectrums for Reflux technique in diethyl ether co-solvent 
Salicylic acid and Lactic acid (2:1) molar ratio 
FTIR Co-Crystal paradigm spectrum 
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Appendix 4:  
FTIR spectrums for grinding technique in Methanol co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
2 
 
 
63 
 
 
 
FTIR spectrums for grinding technique in Methanol co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
4 
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FTIR spectrums for grinding technique in Methanol co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
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Appendix 5:  
FTIR spectrums for grinding technique in Methanol co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
2 
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FTIR spectrums for grinding technique in Methanol co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
4 
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FTIR spectrums for grinding technique in Methanol co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
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Appendix 6:  
 
FTIR spectrums for Reflux technique in Methanol co-solvent 
Salicylic acid and Lactic acid (2:1) molar ration 
FTIR Co-Crystal paradigm spectrum 
 
 
Salicylic acid and Lactic acid (2:2) molar ratio 
FTIR Co-Crystal paradigm spectrum 
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Appendix 7:  
FTIR spectrums for grinding technique in Ethanol co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
 
2 
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FTIR spectrums for grinding technique in Ethanol co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
 
4 
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FTIR spectrums for grinding technique in Ethanol co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
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Appendix 8:  
FTIR spectrums for grinding technique in Ethanol co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
2 
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FTIR spectrums for grinding technique in Ethanol co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
 
4 
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FTIR spectrums for grinding technique in Ethanol co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
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Appendix 9:  
FTIR spectrums for Reflux technique in Ethanol co-solvent  
Salicylic acid and Lactic acid (2:1) 
FTIR Co-Crystal paradigm spectrum 
 
 
Salicylic acid and Lactic acid (2:2) 
FTIR Co-Crystal paradigm spectrum 
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Appendix 10:  
 
FTIR spectrums for grinding technique in Acetonitrile co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
 
2 
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FTIR spectrums for grinding technique in Acetonitrile co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
 
4 
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FTIR spectrums for grinding technique in Acetonitrile co-solvent 
Variable Salicylic acid and Constant Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
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Appendix 11:  
 
FTIR spectrums for grinding technique in Acetonitrile co-solvent  
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
1 
 
 
 
 
2 
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FTIR spectrums for grinding technique in Acetonitrile co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
3 
 
 
 
4 
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FTIR spectrums for grinding technique in Acetonitrile co-solvent 
Constant Salicylic acid and Variable Lactic acid 
Tube # FTIR Co-Crystal paradigm spectrum 
5 
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Appendix 12:  
 
FTIR spectrums for Reflux technique in Acetonitrile co-solvent 
Salicylic acid and Lactic acid (2:1) molar ratio 
FTIR Co-Crystal paradigm spectrum 
 
 
 
Salicylic acid and Lactic acid (2:2) molar ratio 
FTIR Co-Crystal paradigm spectrum 
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Co-crystal sample melting Range is 127.6-127.7°C 
 
Co-crystal sample melting Range is 138.3-139.4°C 
 
Figure 31 Co-crystal sample melting point ranges 
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Co-crystal sample melting Range is 141.5-147.8°C 
 
Co-crystal sample melting Range is 145.2-149.1°C 
 
Figure 32 Co-crystal sample melting point ranges 
 
